For a lot of men with obesity, the most effective ED treatment isn’t a pill — it’s losing 10 to 15 percent of your body weight. ED is mostly a plumbing problem, the fat is what’s clogging the plumbing, and the drugs that now take that weight off reliably are GLP-1 medications.
ED is a vascular disease wearing a sexual costume
An erection is a blood-flow event. The endothelium — the one-cell-thick lining of your arteries — has to release nitric oxide and let the penile vessels dilate. Obesity and insulin resistance poison that process, which is why erectile dysfunction so often arrives years before a heart attack and is treated as an early cardiovascular warning, not just a bedroom complaint. That link is settled cardiology.
Weight loss reverses endothelial dysfunction. In men with obesity and ED, dropping body weight improves erectile function — the direction is consistent and the mechanism is clean. We’re not going to hand you a precise “X pounds buys Y points” figure, because the older lifestyle-weight-loss trials that measured ED scores are small and pre-date the current drugs. The magnitude is real; the exact number is softer than the mechanism.
Here’s the strongest indirect evidence the same weight loss protects the same vessels: in SELECT (Lincoff et al., NEJM 2023; 17,604 adults with overweight or obesity and established cardiovascular disease, no diabetes), semaglutide 2.4 mg cut major adverse cardiovascular events by 20 percent relative to placebo (hazard ratio 0.80). The drug that takes the weight off is also demonstrably protecting arteries — and penile arteries are arteries.
What the weight-loss drugs actually deliver
Two trials set the expectation. In STEP 1 (Wilding et al., NEJM 2021; 1,961 adults with obesity, no diabetes), semaglutide 2.4 mg weekly produced −14.9% mean body weight at 68 weeks versus −2.4% on placebo. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; 2,539 adults), tirzepatide reached −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg over 72 weeks versus −3.1% on placebo. Those numbers land squarely in the range where erectile function tends to improve.
The mechanism is textbook, not vibes. GLP-1 receptor agonists slow gastric emptying, act on appetite circuits in the hypothalamus and hindbrain, and improve insulin secretion. Tirzepatide adds GIP receptor agonism on top. The nausea everyone asks about follows directly from delayed gastric emptying, which is why it tracks dose escalation and fades as titration slows — it isn’t random.
The protocol we actually run
For a man with ED and a BMI of 27 or higher, we start a GLP-1 and use an on-demand PDE5 inhibitor — sildenafil or tadalafil — during the early months while the weight is still coming off. As the weight comes off, the expectation is that the on-demand pill is needed less often, and some men can taper it — but that’s the direction the vascular biology predicts, not a guaranteed result. If bloodwork shows genuinely low testosterone, TRT is a reasonable add; the point is to fix the vascular substrate, not just override it at showtime.
Semaglutide titration is deliberate: 0.25 mg weekly to start, stepping roughly every four weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), and slower if side effects show up. That slow ramp is the nausea-management strategy, not bureaucracy.
The part people skip: this is a maintenance drug
The weight loss holds only while the drug does. In STEP 4 (Rubino et al., JAMA 2021), stopping semaglutide at week 20 led to substantial regain versus continuing. SURMOUNT-4 (Aronne et al., JAMA 2024) is blunter: after 36 weeks of tirzepatide, those switched to placebo regained about 14 percent of body weight over the following year while those who stayed on lost another 5.5 percent. Any erectile benefit that rode in on the weight loss rides back out if you quit without a maintenance plan. Talk to your clinician before stopping — a taper-and-hold plan matters here.
One honest caveat. DXA substudies of these trials show a meaningful fraction of the weight lost is lean mass, not just fat. The countermeasure is resistance training plus protein intake in the 1.2–1.6 g/kg/day range clinicians commonly target. Long-term functional consequences of that lean-mass loss aren’t yet well characterized, so we manage it rather than ignore it.
Where this is still open
No trial has yet compared GLP-1-driven weight loss against equivalent lifestyle weight loss using erectile function as the endpoint. We’re extrapolating from strong weight and cardiovascular data to a sexual outcome the drug trials didn’t formally measure. That’s a reasonable extrapolation given the shared vascular biology — but it’s the trial we’d most want to see run.
Not sure where you land? Start the intake and a US-licensed clinician reviews your case and sets your titration. Zappy is cash-pay, no insurance required, FSA/HSA eligible; our compounded semaglutide and tirzepatide are prepared by LegitScript-verified 503A US pharmacies under physician oversight, and are not FDA-approved or FDA-approved generics or equivalents of the branded drugs. Compounded preparations are not FDA-approved.
